Fengate Private Equity Acquires Majority Stake in Clinical Research of West Florida

Skip to Content News Archives Economy Defence Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Defence Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Defence Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Fengate Private Equity Acquires Majority Stake in Clinical Research of West FloridaAuthor of the article:Investment extends Fengate’s pharma services strategy from commercialization into clinical developmentTHIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountTAMPA & CLEARWATER, FL, Oct. 13, 2026 (GLOBE NEWSWIRE) — Fengate Private Equity, a division of Fengate Asset Management (“Fengate”), is pleased to announce it has acquired a majority stake in Clinical Research of West Florida (“CRWF” or “the Company”), an independent clinical research site network serving the Tampa Bay region. The investment marks the healthcare team’s second pharma services platform investment, extending Fengate’s coverage from commercialization into clinical development. Fengate is managing this investment on behalf of the LiUNA Pension Fund of Central and Eastern Canada (LPFCEC).This advertisement has not loaded yet, but your article continues below.Founded in 1995 by Lynne Merriam and led since 2002 by President Aydin Keskiner, CRWF operates three state-of-the-art research facilities across Tampa and Clearwater, including a dedicated Phase I unit. Six board-certified principal investigators lead the company’s clinical team with deep expertise in autoimmune, pulmonology and endocrinology, among other therapeutic areas. CRWF has supported more than 1,000 trials across Phase I through IV for nearly 300 global biopharmaceutical sponsors and contract research organizations (CROs).Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againWith Fengate’s support, CRWF will expand its trial capacity through continued investment in talent, site infrastructure, and therapeutic depth. The Company will seek to partner with independent sites that have strong investigators and established patient communities, alongside new site development.“Sponsors and CROs increasingly need site partners that can deliver consistent enrollment, quality and execution at scale,” said Maxim Tcherner, Managing Director at Fengate Private Equity. “CRWF has built an exceptional 30-year track record defined by strong patient care, clinical excellence and trusted sponsor relationships. Clinical research is a priority within our healthcare strategy, and we believe CRWF is the right platform to build a leading regional network while preserving the qualities that have made the company successful.”This advertisement has not loaded yet, but your article continues below.“Advancing science and improving lives has been our mission since inception. We have built CRWF as a family business, site by site, with investigators and a clinical team that has been with us for decades,” said Aydin Keskiner, President at CRWF. “Fengate brings the capital, industry expertise, and sponsor relationships to expand beyond Southwestern Florida. We’ll grow CRWF opening new sites in high-demand markets and partnering with independent site owners who want the resources to grow. What we won’t change is the experience patients have here.”Westcove Partners served as financial advisors to CRWF. Financial terms of the transaction were not disclosed.About Clinical Research of West FloridaClinical Research of West Florida (CRWF) is an independent clinical research site network serving the Tampa Bay area. Founded in 1995, CRWF operates three research facilities across Tampa and Clearwater, including a dedicated Phase I unit. Its team of board-certified principal investigators has supported more than 1,000 clinical trials across Phase I through IV, with experience in autoimmune, pulmonology, endocrinology, among others. CRWF partners with biopharmaceutical sponsors and contract research organizations and draws on a database of more than 35,000 patients. Learn more at www.crwf.com.This advertisement has not loaded yet.This advertisement has not loaded yet, but your article continues below.About Fengate Asset ManagementFengate Asset Management is a leading alternative investment manager, with more than $19+ billion in assets under management, focused on private equity, infrastructure and real estate strategies. With offices and team members across Canada and the United States, Fengate leverages more than 50 years of entrepreneurial experience to deliver excellent investment results on behalf of its clients. Fengate Private Equity, a division of Fengate Asset Management, is a differentiated investment platform supporting the growth ambitions of entrepreneurs through transformative capital. Learn more at www.fengate.com.Vanessa Naughton Fengate Asset Management +1 416-709-3962 media@fengate.com This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.